MEI Other Stockholder Equity vs Accounts Payable Analysis
MEIP Stock | USD 2.55 0.15 5.56% |
MEI Pharma financial indicator trend analysis is infinitely more than just investigating MEI Pharma recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether MEI Pharma is a good investment. Please check the relationship between MEI Pharma Other Stockholder Equity and its Accounts Payable accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MEI Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in MEI Stock, please use our How to Invest in MEI Pharma guide.
Other Stockholder Equity vs Accounts Payable
Other Stockholder Equity vs Accounts Payable Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of MEI Pharma Other Stockholder Equity account and Accounts Payable. At this time, the significance of the direction appears to have strong relationship.
The correlation between MEI Pharma's Other Stockholder Equity and Accounts Payable is 0.73. Overlapping area represents the amount of variation of Other Stockholder Equity that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of MEI Pharma, assuming nothing else is changed. The correlation between historical values of MEI Pharma's Other Stockholder Equity and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Stockholder Equity of MEI Pharma are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Other Stockholder Equity i.e., MEI Pharma's Other Stockholder Equity and Accounts Payable go up and down completely randomly.
Correlation Coefficient | 0.73 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Other Stockholder Equity
Accounts Payable
An accounting item on the balance sheet that represents MEI Pharma obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of MEI Pharma are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Most indicators from MEI Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into MEI Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MEI Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in MEI Stock, please use our How to Invest in MEI Pharma guide.At this time, MEI Pharma's Selling General Administrative is relatively stable compared to the past year. As of 12/16/2024, Enterprise Value Over EBITDA is likely to grow to 0.61, while Issuance Of Capital Stock is likely to drop 0.00.
MEI Pharma fundamental ratios Correlations
Click cells to compare fundamentals
MEI Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
MEI Pharma fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 209.7M | 174.1M | 177.8M | 120.8M | 41.4M | 62.7M | |
Other Current Liab | 6.1M | 7.5M | 9.9M | 11.0M | 5.2M | 3.9M | |
Total Current Liabilities | 23.3M | 30.3M | 24.4M | 20.3M | 8.4M | 8.3M | |
Total Stockholder Equity | 78.2M | 41.4M | 52.4M | 24.6M | 33.0M | 32.7M | |
Net Debt | (12.3M) | (245K) | (6.1M) | (4.2M) | (3.7M) | (3.9M) | |
Accounts Payable | 2.4M | 6.4M | 7.9M | 6.1M | 3.2M | 2.2M | |
Cash | 12.3M | 8.5M | 15.7M | 16.9M | 3.7M | 3.5M | |
Cash And Short Term Investments | 182.6M | 153.4M | 153.3M | 100.7M | 38.3M | 57.3M | |
Common Stock Shares Outstanding | 4.6M | 5.7M | 6.3M | 6.7M | 6.7M | 7.0M | |
Liabilities And Stockholders Equity | 209.7M | 174.1M | 177.8M | 120.8M | 41.4M | 62.7M | |
Other Current Assets | 5.6M | 3.8M | 7.7M | 11.3M | 2.4M | 1.9M | |
Other Stockholder Equity | 355.5M | 369.2M | 426.6M | 430.6M | 421.2M | 442.3M | |
Total Liab | 131.5M | 132.7M | 125.4M | 96.2M | 8.4M | 7.9M | |
Total Current Assets | 208.6M | 164.8M | 167.1M | 107.5M | 40.8M | 60.9M | |
Retained Earnings | (277.2M) | (327.8M) | (374.2M) | (406.0M) | (388.2M) | (368.8M) | |
Short Term Investments | 170.3M | 144.9M | 137.5M | 83.8M | 34.6M | 32.9M | |
Non Current Liabilities Total | 46.3M | 20.4M | 108.2M | 102.4M | 101.0M | 75.8M | |
Property Plant And Equipment Net | 1.1M | 9.3M | 10.7M | 13.3M | 606K | 575.7K | |
Non Current Assets Total | 1.1M | 9.3M | 10.7M | 13.3M | 606K | 575.7K | |
Property Plant And Equipment Gross | 1.1M | 9.3M | 11.4M | 14.3M | 2.4M | 2.9M | |
Property Plant Equipment | 1.1M | 9.3M | 10.7M | 13.3M | 15.3M | 16.0M | |
Net Tangible Assets | 78.2M | 41.4M | 52.4M | 24.6M | 28.3M | 48.6M | |
Retained Earnings Total Equity | (214.4M) | (231.2M) | (277.2M) | (327.8M) | (295.0M) | (309.8M) | |
Capital Surpluse | 264.9M | 279.1M | 355.5M | 369.2M | 424.5M | 255.0M | |
Non Currrent Assets Other | (1.1M) | (9.3M) | (10.7M) | (13.3M) | (12.0M) | (11.4M) | |
Current Deferred Revenue | 14.8M | 14.6M | 4.8M | 317K | 364.6K | 346.3K | |
Net Invested Capital | 78.2M | 41.4M | 52.4M | 24.6M | 33.0M | 37.9M | |
Net Working Capital | 185.3M | 134.5M | 142.7M | 87.2M | 32.4M | 30.8M | |
Other Liab | 108.2M | 95.1M | 92.2M | 64.5M | 74.2M | 78.2M | |
Net Receivables | 20.4M | 7.6M | 10.0M | 85K | 76.5K | 72.7K |
Pair Trading with MEI Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if MEI Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in MEI Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against MEI Stock
0.55 | FLGC | Flora Growth Corp | PairCorr |
0.37 | DYAI | Dyadic International | PairCorr |
0.35 | DNA | Ginkgo Bioworks Holdings | PairCorr |
0.32 | ESPR | Esperion Therapeutics | PairCorr |
0.32 | IMAB | I Mab | PairCorr |
The ability to find closely correlated positions to MEI Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace MEI Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back MEI Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling MEI Pharma to buy it.
The correlation of MEI Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as MEI Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if MEI Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for MEI Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for MEI Stock Analysis
When running MEI Pharma's price analysis, check to measure MEI Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MEI Pharma is operating at the current time. Most of MEI Pharma's value examination focuses on studying past and present price action to predict the probability of MEI Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MEI Pharma's price. Additionally, you may evaluate how the addition of MEI Pharma to your portfolios can decrease your overall portfolio volatility.